COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00107354
Recruitment Status : Completed
First Posted : April 6, 2005
Last Update Posted : September 20, 2010
Information provided by:
Fred Hutchinson Cancer Research Center

Brief Summary:

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop cancer cells from growing.

PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes that relapsed after donor stem cell transplant.

Condition or disease Intervention/treatment Phase
Leukemia Myelodysplastic Syndromes Biological: aldesleukin Biological: therapeutic allogeneic lymphocytes Biological: therapeutic autologous lymphocytes Drug: cytarabine Drug: etoposide Drug: mitoxantrone hydrochloride Procedure: allogeneic bone marrow transplantation Procedure: peripheral blood stem cell transplantation Phase 1

Detailed Description:



  • Determine the toxic effects of adoptive immunotherapy comprising CD8-positive minor histocompatability antigen-specific cytotoxic T-lymphocytes in patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes that relapsed after allogeneic hematopoietic stem cell transplantation.


  • Determine the persistence of adoptively transfused T cells in vivo and assess their migration to the bone marrow in these patients.
  • Determine the anti-leukemic activity of this therapy in these patients.

OUTLINE: This is a pilot, open-label, nonrandomized study.

  • Leukapheresis: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMCs) before transplantation. Donors undergo leukapheresis to obtain PBMCs to use as feeder cells for generating adoptive immunotherapy. Patient PBMCs are combined with donor PBMCs and expanded in vitro to generate CD8-positive minor histocompatability antigen-specific cytotoxic T-lymphocytes (CTLs) for adoptive immunotherapy.
  • Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Patients with a morphologic or flow cytometric relapse on or after day 100 post-transplantation proceed to cytoreductive chemotherapy. Patients with a molecular or cytogenetic relapse on or after day 100 post-transplantation proceed directly to adoptive immunotherapy. Patients with relapsed disease before day 100 post-transplantation are eligible to receive adoptive immunotherapy at a later date provided the patient continues to relapse and CTLs are available.
  • Cytoreductive chemotherapy: The chemotherapy regimen for each patient is determined after consideration of prior chemotherapy, type of leukemia, and other clinical parameters. Two regimens to consider are:

    • Mitoxantrone IV and etoposide IV on days -6 to -2
    • High-dose cytarabine IV over 2 hours twice daily on days -6, -4, and -2 Patients achieving a complete remission after completion of cytoreductive chemotherapy proceed to adoptive immunotherapy.
  • Adoptive immunotherapy: Within 2-3 days after completion of cytoreductive chemotherapy, patients receive CTLs IV over 1-2 hours on days 0, 4, 11, 21, and 28 in the absence of unacceptable toxicity. Patients with evidence of persistent disease on or after day 35 OR relapsed disease after an initial response to CTLs receive a sixth infusion of CTLs followed, no more than 24 hours later, by interleukin-2 subcutaneously once daily for up 14 total doses in the absence of unacceptable toxicity. Patients with subsequent relapsed disease after day 48 may be eligible for retreatment.

After completion of study treatment, patients are followed with bone marrow aspiration every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 25-30 patients (10-15 with acute myeloid leukemia or myelodysplastic syndromes AND 10-15 with acute lymphoblastic leukemia) will be accrued for this study within 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant
Study Start Date : December 1998
Actual Primary Completion Date : August 2009

Primary Outcome Measures :
  1. Toxicity

Secondary Outcome Measures :
  1. In vivo persistence of adoptively transferred T cells
  2. Migration of adoptively transferred T cells to the bone marrow
  3. Antileukemic activity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Undergoing allogeneic hematopoietic stem cell transplantation* from a major histocompatability complex (MHC)-identical related donor for 1 of the following:

    • Primary refractory acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)
    • AML or ALL beyond first remission
    • Therapy-related AML at any stage
    • Philadelphia chromosome (bcr-abl)-positive p190-positive ALL at any stage
    • Acute leukemia at any stage arising from myelodysplastic syndromes or myeloproliferative disorders, including any of the following:

      • Chronic myelomonocytic leukemia
      • Chronic myelogenous leukemia
      • Polycythemia vera
      • Essential thrombocytosis
      • Agnogenic myeloid metaplasia with myelofibrosis
    • Refractory anemia with excess blasts
    • Refractory anemia with excess blasts in transformation NOTE: *Patients must be enrolled on study prior to undergoing transplantation
  • Relapsed disease post-transplantation, as evidenced by 1 of the following criteria:

    • Morphologic relapse, as defined by 1 or more of the following:

      • Peripheral blasts in the absence of growth factor therapy
      • Bone marrow blasts > 5% of nucleated cells
      • Extramedullary chloroma or granulocytic sarcoma
    • Flow cytometric relapse, as defined by the appearance of cells with abnormal immunophenotype consistent with leukemia relapse in the peripheral blood or bone marrow (detected before transplantation)
    • Cytogenetic relapse, as defined by the appearance in 1 or more metaphases from bone marrow or peripheral blood cells of either a non-constitutional cytogenetic abnormality detected in at least 1 cytogenetic study performed before transplantation OR a new abnormality known to be associated with leukemia
    • Molecular relapse, as defined by 1 of the following:

      • 1 or more positive polymerase chain reaction (PCR) assays for clonotypic immunoglobulin heavy chain or T-cell receptor gene rearrangement in patients transplanted for B- or T-cell ALL respectively
      • 1 or more positive post-transplantation reverse transcription PCR assays for p190 BCR-ABL mRNA fusion transcripts in patients transplanted for Philadelphia chromosome-positive p190-positive ALL
  • No grade III or IV acute graft-versus-host disease (GVHD)**
  • No extensive chronic GVHD** NOTE: **At time of post-transplant relapse



  • 14 and over (patients < 14 years of age may be eligible if they are deemed to be of sufficient height and weight by the pediatric attending physician)

Performance status

  • Karnofsky 60-100% (at time of post-transplant relapse)

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No preexisting major nonhematopoietic organ toxicity ≥ grade 3 (at time of post-transplant relapse)


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Concurrent immunosuppressive steroid therapy for GVHD allowed provided both of the following are true:

    • Able to taper steroid dose to < 0.5 mg/kg/day
    • No increase of > 1 grade in acute GVHD OR progression of chronic GVHD within 14 days after dose change


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00107354

Layout table for location information
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Layout table for investigator information
Principal Investigator: Edus H. Warren, MD, PhD Fred Hutchinson Cancer Research Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00107354    
Other Study ID Numbers: 1334.00
First Posted: April 6, 2005    Key Record Dates
Last Update Posted: September 20, 2010
Last Verified: September 2010
Keywords provided by Fred Hutchinson Cancer Research Center:
recurrent adult acute lymphoblastic leukemia
recurrent adult acute myeloid leukemia
recurrent childhood acute lymphoblastic leukemia
recurrent childhood acute myeloid leukemia
secondary acute myeloid leukemia
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
T-cell adult acute lymphoblastic leukemia
T-cell childhood acute lymphoblastic leukemia
B-cell adult acute lymphoblastic leukemia
B-cell childhood acute lymphoblastic leukemia
childhood myelodysplastic syndromes
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents